Equillium, Inc. (EQ)
1.27
-0.15
(-10.56%)
USD |
NASDAQ |
Oct 22, 16:00
1.26
-0.01
(-0.79%)
After-Hours: 20:00
Equillium Enterprise Value : 23.95M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 23.95M |
| October 21, 2026 | 33.46M |
| October 20, 2026 | 30.92M |
| October 19, 2026 | 22.05M |
| October 16, 2026 | 18.88M |
| October 15, 2026 | 27.12M |
| October 14, 2026 | 25.85M |
| October 13, 2026 | 27.12M |
| October 12, 2026 | 38.53M |
| October 09, 2026 | 32.83M |
| October 08, 2026 | 34.73M |
| October 07, 2026 | 31.56M |
| October 06, 2026 | 33.46M |
| October 05, 2026 | 35.36M |
| October 02, 2026 | 32.83M |
| October 01, 2026 | 41.07M |
| September 30, 2026 | 46.46M |
| September 29, 2026 | 46.14M |
| September 28, 2026 | 49.95M |
| September 25, 2026 | 49.31M |
| September 24, 2026 | 52.48M |
| September 23, 2026 | 54.38M |
| September 22, 2026 | 65.80M |
| September 21, 2026 | 63.58M |
| September 18, 2026 | 65.16M |
| Date | Value |
|---|---|
| September 17, 2026 | 63.26M |
| September 16, 2026 | 61.04M |
| September 15, 2026 | 73.41M |
| September 14, 2026 | 76.26M |
| September 11, 2026 | 77.21M |
| September 10, 2026 | 96.87M |
| September 09, 2026 | 105.74M |
| September 08, 2026 | 96.23M |
| September 04, 2026 | 83.55M |
| September 03, 2026 | 84.19M |
| September 02, 2026 | 86.09M |
| September 01, 2026 | 83.23M |
| August 31, 2026 | 87.36M |
| August 28, 2026 | 94.97M |
| August 27, 2026 | 98.77M |
| August 26, 2026 | 93.06M |
| August 25, 2026 | 81.65M |
| August 24, 2026 | 82.92M |
| August 21, 2026 | 89.89M |
| August 20, 2026 | 87.36M |
| August 19, 2026 | 91.16M |
| August 18, 2026 | 92.43M |
| August 17, 2026 | 100.67M |
| August 14, 2026 | 93.06M |
| August 13, 2026 | 70.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.613B |
| Alnylam Pharmaceuticals, Inc. | 30.07B |
| Anika Therapeutics, Inc. | 269.09M |
| Savara, Inc. | 789.89M |
| Vericel Corp. | 2.131B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.693M |
| Total Expenses (Quarterly) | 4.693M |
| EPS Diluted (Quarterly) | -0.042 |
| Earnings Yield | -15.99% |
| Normalized Earnings Yield | -15.98 |